{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:07:15Z","timestamp":1762520835145,"version":"build-2065373602"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T00:00:00Z","timestamp":1592179200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"SBI Pharmaceuticals Co., Ltd"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials Communications"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.conctc.2020.100593","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T02:56:17Z","timestamp":1592362577000},"page":"100593","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["A prospective study of oral 5-aminolevulinic acid to prevent adverse events in patients with localized prostate cancer undergoing low-dose-rate brachytherapy: Protocol of the AMBER study"],"prefix":"10.1016","volume":"19","author":[{"given":"Makito","family":"Miyake","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9242-7877","authenticated-orcid":false,"given":"Nobumichi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Asakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Yamaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9672-2117","authenticated-orcid":false,"given":"Takashi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunta","family":"Hori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasushi","family":"Nakai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Anai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"Torimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Toritsuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8419-2008","authenticated-orcid":false,"given":"Shinji","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7207-4127","authenticated-orcid":false,"given":"Tomomi","family":"Fujii","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiho","family":"Ohbayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masato","family":"Kasahara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyohide","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.conctc.2020.100593_bib1","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s10147-014-0704-4","article-title":"Nationwide Japanese prostate cancer outcome study of permanent iodine-125 seed implantation (J-POPS)","volume":"20","author":"Saito","year":"2015","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.conctc.2020.100593_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/iju.14098","article-title":"Low-dose-rate brachytherapy for prostate cancer: a 15-year experience in Japan","volume":"27","author":"Tanaka","year":"2020","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.conctc.2020.100593_bib3","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12894-017-0251-1","article-title":"Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute","volume":"17","author":"Miyake","year":"2017","journal-title":"BMC Urol."},{"key":"10.1016\/j.conctc.2020.100593_bib4","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1748-717X-8-25","article-title":"Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy","volume":"8","author":"Tanaka","year":"2013","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.conctc.2020.100593_bib5","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.eururo.2011.09.027","article-title":"Functional outcomes and complications following radiation therapy for prostate cancer: a critical analysis of the literature","volume":"61","author":"Bud\u00e4us","year":"2012","journal-title":"Eur. Urol."},{"key":"10.1016\/j.conctc.2020.100593_bib6","first-page":"20180008","article-title":"Expanding the therapeutic index of radiation therapy by normal tissue protection","author":"Montay-Gruel","year":"2018","journal-title":"Br. J. Radiol."},{"key":"10.1016\/j.conctc.2020.100593_bib7","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/pros.23740","article-title":"Dual benefit of supplementary oral 5-aminolevulinic acid to pelvic radiotherapy in a syngenic prostate cancer model","volume":"79","author":"Miyake","year":"2019","journal-title":"Prostate"},{"key":"10.1016\/j.conctc.2020.100593_bib8","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1111\/j.1751-1097.2009.00543.x","article-title":"siRNA-mediated knockdown of the heme synthesis and degradation pathways: modulation of treatment effect of 5-aminolevulinic acid-based photodynamic therapy in urothelial cancer cell lines","volume":"85","author":"Miyake","year":"2009","journal-title":"Photochem. Photobiol."},{"key":"10.1016\/j.conctc.2020.100593_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080850","article-title":"5-Aminolevulinic acid protects against cisplatin-induced nephrotoxicity without compromising the anticancer efficiency of cisplatin in rats in vitro and in vivo","volume":"8","author":"Terada","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.conctc.2020.100593_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/nep.13189","article-title":"5-aminolevulinic acid exerts renoprotective effect via Nrf2 activation in murine rhabdomyolysis-induced acute kidney injury","volume":"24","author":"Uchida","year":"2019","journal-title":"Nephrology"},{"key":"10.1016\/j.conctc.2020.100593_bib11","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.1038\/s41598-017-06406-6","article-title":"Neuroprotective effect of 5-aminolevulinic acid against low inorganic phosphate in neuroblastoma SH-SY5Y cells","volume":"7","author":"Takase","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.conctc.2020.100593_bib12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.bbrc.2016.09.156","article-title":"5-Aminolevulinic acid with sodium ferrous citrate induces autophagy and protects cardiomyocytes from hypoxia-induced cellular injury through MAPK-Nrf-2-HO-1 signaling cascade","volume":"479","author":"Zhao","year":"2016","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.conctc.2020.100593_bib13","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1442-2042.2008.02172.x","article-title":"Technical acquisition and dosimetric assessment of iodine-125 permanent brachytherapy in localized prostate cancer: our first series of 100 patients","volume":"16","author":"Tanaka","year":"2009","journal-title":"Int. J. Urol."},{"key":"10.1016\/j.conctc.2020.100593_bib14","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1186\/s13014-014-0302-7","article-title":"Use of alpha-1 adrenoceptor antagonists in patients who underwent low-dose-rate brachytherapy for prostate cancer - a randomized controlled trial of silodosin versus naftopidil","volume":"9","author":"Tanaka","year":"2014","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.conctc.2020.100593_bib15","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/j.juro.2008.11.127","article-title":"Evaluation and treatment of lower urinary tract symptoms in older men","volume":"181","author":"Abrams","year":"2009","journal-title":"J. Urol."},{"key":"10.1016\/j.conctc.2020.100593_bib16","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","article-title":"Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference","volume":"65","author":"Roach","year":"2006","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.conctc.2020.100593_bib17","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.urology.2008.12.062","article-title":"Variations in international prostate symptom scores, uroflowmetric parameters, and prostate volume after (125)I permanent brachytherapy for localized prostate cancer","volume":"74","author":"Tanaka","year":"2009","journal-title":"Urology"},{"key":"10.1016\/j.conctc.2020.100593_bib18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.5114\/jcb.2019.88142","article-title":"Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer","volume":"11","author":"Nakai","year":"2019","journal-title":"J. Contemp. Brachytherapy"},{"key":"10.1016\/j.conctc.2020.100593_bib19","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.brachy.2014.09.009","article-title":"Urethral toxicity after LDR brachytherapy: experience in Japan","volume":"14","author":"Tanaka","year":"2015","journal-title":"Brachytherapy"},{"key":"10.1016\/j.conctc.2020.100593_bib20","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.brachy.2017.12.004","article-title":"Comparison of chronological changes in urinary function in patients who underwent low-dose-rate brachytherapy for prostate cancer-A randomized controlled trial of alpha-1 adrenoceptor antagonist alone versus combination with cyclooxygenase-2 inhibitor","volume":"17","author":"Tanaka","year":"2018","journal-title":"Brachytherapy"},{"key":"10.1016\/j.conctc.2020.100593_bib21","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1007\/s00066-017-1162-5","article-title":"Does combination therapy with tamsulosin and trospium chloride improve lower urinary tract symptoms after SEEDS brachytherapy for prostate cancer compared with tamsulosin alone?: a prospective, randomized, controlled trial","volume":"193","author":"Yan","year":"2017","journal-title":"Strahlenther. Onkol."},{"key":"10.1016\/j.conctc.2020.100593_bib22","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1757-5672.2011.00100.x","article-title":"Suppressive effects of eviprostat, a phytotherapeutic agent, on lower urinary tract symptoms in prostate cancer patients treated with brachytherapy","volume":"4","author":"Tanaka","year":"2012","journal-title":"Low. Urin. Tract. Symptoms"},{"key":"10.1016\/j.conctc.2020.100593_bib23","first-page":"8294805","article-title":"The safety and tolerability of 5-aminolevulinic acid phosphate with sodium ferrous citrate in patients with type 2 diabetes mellitus in Bahrain","author":"Al-Saber","year":"2016","journal-title":"J. Diabetes. Res."},{"key":"10.1016\/j.conctc.2020.100593_bib24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1152\/japplphysiol.00582.2015","article-title":"Impact of 5-aminolevulinic acid with iron supplementation on exercise efficiency and home-based walking training achievement in older women","volume":"120","author":"Masuki","year":"2016","journal-title":"J. Appl. Physiol."},{"key":"10.1016\/j.conctc.2020.100593_bib25","first-page":"3669","article-title":"The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review","volume":"24","author":"Atkinson","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.conctc.2020.100593_bib26","first-page":"2959","article-title":"Impact of oxaliplatin-induced neuropathy: a patient perspective","volume":"20","author":"Bennett","year":"2012","journal-title":"Support Care Cancer"}],"container-title":["Contemporary Clinical Trials Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865420300776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2451865420300776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:02:36Z","timestamp":1762520556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2451865420300776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":26,"alternative-id":["S2451865420300776"],"URL":"https:\/\/doi.org\/10.1016\/j.conctc.2020.100593","relation":{},"ISSN":["2451-8654"],"issn-type":[{"type":"print","value":"2451-8654"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A prospective study of oral 5-aminolevulinic acid to prevent adverse events in patients with localized prostate cancer undergoing low-dose-rate brachytherapy: Protocol of the AMBER study","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.conctc.2020.100593","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"100593"}}